Quantitative in vivo receptor binding III: Tracer kinetic modeling of muscarinic cholinergic receptor binding.

Por Frey, K A, Hichwa, R D, Ehrenkaufer, R L, Agranoff, B W
Publicado em 1985

Striatal [(11)C]dihydrotetrabenazine and [(11)C]methylphenidate binding in Tourette syndrome

Por Albin, R L., Koeppe, R A., Wernette, K, Zhuang, W, Nichols, T, Kilbourn, M R., Frey, K A.
Publicado em 2009

Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease

Por Ridder, A., Müller, M.L.T.M., Kotagal, V., Frey, K.A., Albin, R.L., Bohnen, N.I.
Publicado no Parkinsonism Relat Disord (2016)

History of falls in Parkinson disease is associated with reduced cholinergic activity

Por Bohnen, N I., Müller, M L.T.M., Koeppe, R A., Studenski, S A., Kilbourn, M A., Frey, K A., Albin, R L.
Publicado em 2009

Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options

Por Ludolph, A. C., Kassubek, J., Landwehrmeyer, B. G., Mandelkow, E., Mandelkow, E.-M., Burn, D. J., Caparros-Lefebvre, D., Frey, K. A., de Yebenes, J. G., Gasser, T., Heutink, P., Höglinger, G., Jamrozik, Z., Jellinger, K. A., Kazantsev, A., Kretzschmar, H., Lang, A. E., Litvan, I., Lucas, J. J., McGeer, P. L., Melquist, S., Oertel, W., Otto, M., Paviour, D., Reum, T., Saint-Raymond, A., Steele, J. C., Tolnay, M., Tumani, H., van Swieten, J. C., Vanier, M. T., Vonsattel, J.-P., Wagner, S., Wszolek, Z. K.
Publicado em 2009